Drug
GFH375
GFH375 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_3
1
25%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Terminated(1)
Detailed Status
Recruiting2
Not yet recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
not_yet_recruiting125%
recruiting250%
withdrawn125%
Recent Activity
2 active trials
Showing 4 of 4
not_yet_recruitingphase_3
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
NCT07262567
recruitingphase_1
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
NCT07259590
recruitingphase_1
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676
withdrawnphase_2
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
NCT07026916
Clinical Trials (4)
Showing 4 of 4 trials
NCT07262567Phase 3
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
NCT07259590Phase 1
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
NCT06500676Phase 1
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT07026916Phase 2
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4